Legend Biotech Corporation

Legend Biotech Corporation

LEGNยทNASDAQ

$35.98

+3.1%
HealthcareBiotechnology

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

At a Glance

Live Snapshot
Market Cap$6.65B
EPS-1.6000
P/E Ratio-22.49
Earnings Date08/10/2026

No Dividend Yield Data

LEGN has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

LEGN has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

LEGN has not reported any net dividends paid values in the available annual periods.

Legend Biotech Corporation

Legend Biotech Corporation Dividend History

LEGN ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

LEGN Dividend Payment History

LEGN ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
legn

Legend Biotech Corporation Payout Ratio Analysis

LEGN ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-297.58M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.